Lakefront Biotherapeutics (LFBT) Stock Coverage Resumed at Equalweight

Morgan Stanley resumed coverage of Lakefront Biotherapeutics (LFBT) with an Equalweight rating. The firm has not issued any specific price target or earnings forecasts for the stock. This coverage resumption may signal a neutral outlook for investors regarding LFBT's potential performance. The update is relevant for those monitoring the biotherapeutics sector and Lakefront's market position. Investors should consider such ratings as they can influence trading strategies and stock price movements.